Recent data demonstrated that inhibition of GLI1 and SMO increase the activity of Ara-C for AML; thus, combination therapy for Hh pathway, SKY, and FLT3 is an acceptable and comprehensive therapeutic candidate and may improve clinical outcomes [31]. Here, TYRO3 is linked to acute myeloid leukemia.